510(k) Report

510(k) · Cleared

Recalled · Class II · 2025

HardyCHROM CRE

K190553510(k) TraditionalCleared Apr 29, 201955-day reviewClass II21 CFR 866.1700Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Hardy Diagnostics · JSO Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar

Cleared on Apr 29, 2019 as substantially equivalent to K122187 (Bio-Rad, 2012) after a 55-day review. Its family tree reaches back 2 generations to 1997. It has been recalled once.

Decided
Apr 29, 2019
Review
55 days
Class
Class II
Product code
JSO
Recalls
1
Predicates
1

Its longest line of descent runs back 2 generations to K972359 (1997). 3 ancestors in all. No later device cites it as a predicate yet.

Other ancestors, by year cleared 2010: 1 other ancestorK972359 · Remel Bile Esculin Azide Agar W/6 MCG/ML Vancomycin · Remel, L.P. · 1997 · recalledK122187 · Vreselect Culture Medium · Bio-Rad · 2012199520002005201020152020
Other ancestors, by generation 2 generations back: 1 other ancestor K122187 · Vreselect Culture Medium · Bio-Rad · 2012K972359 · Remel Bile Esculin Azide Agar W/6 MCG/ML Vancomycin · Remel, L.P. · 1997 · recalled0
  1. Root · 2 generations backK972359 Remel Bile Esculin Azide Agar W/6 MCG/ML VancomycinRemel, L.P. · 1997 · Recalled
  2. 1 generation backK122187 Vreselect Culture MediumBio-Rad · 2012
  3. This deviceK190553 HardyCHROM CREHardy Diagnostics · 2019
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K972359Remel Bile Esculin Azide Agar W/6 MCG/ML VancomycinRemel, L.P.19971
−1K122187Vreselect Culture MediumBio-Rad2012—
0 (this device)K190553HardyCHROM CREHardy Diagnostics2019—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
201010
FIG. 1 — Lineage of K190553, 1997–2019Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JSO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K122187Vreselect Culture Medium
Summary page 3
…dyCHROM™ CRE Classification Name: Culture medium for anti-microbial susceptibility tests Regulatory Class: II Product Code: JSO III. PREDICATE DEVICE Bio Rad VRESelect, K122187 IV. DEVICE DESCRIPTION HardyCHROM™ CRE is a selective and differential chromogenic medium designed to screen for carbapenem non-…
Bio-Rad2012—

Also cleared against K122187: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
May 6, 2025Class IIZ-2041-2025Nonconforming Material/ComponentIdentified lots failed incoming quality control testing. Lots exhibited breakthrough growth of Klebsiella pneumoniae.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 22 years and passes through 3 companies; a new generation was cleared every 15.2 years on median.
  • 1 of the 3 ancestors has a recall of any class.
  • 1 other device also cites its predicate K122187.

How does its category compare?

All JSO devices

JSO Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar: FDA decisions, review times, recalls and adverse event reports over 20 years. 2019, this device’s year, is highlighted.

FDA decisions per year · JSO

1in 2019

2007: 12008: 22009: 12010: 52011: 22012: 12016: 32017: 22018: 12019: 1
2007high 5 (2010) · low 0 (2013)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JSO

262in 2016

2010: 326 days median2016: 262 days median
2007high 326 (2010) · low 262 (2016)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · JSO

15in 2022

2007: 22009: 42011: 32017: 22020: 12022: 15
2007high 15 (2022) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JSO

513in 2025

2008: 12010: 12011: 12013: 12015: 322016: 172017: 432018: 142019: 92020: 72021: 272022: 82023: 122024: 42025: 513
2007high 513 (2025) · low 0 (2007)2025

MAUDE reports naming product code JSO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—20
20082—01
20091—40
2010532601
20112—31
20121—00
20130—01
20140—00
20150—032
20163262017
20172—243
20181—014
20191—09
20200—17
20210—027
20220—158
20230—012
20240—04
20250—0513
20260—0—

What is it indicated for?

HardyCHROM™ CRE is a selective and differential chromogenic agar medium intended for the qualitative and presumptive detection from stool specimens of Escherichia coli that are non- susceptible to carbapenems as pink colonies and KES (Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae complex, and Serratia marcescens) that are non-susceptible to carbapenems as blue colonies. HardyCHROM CRE is intended as an aid in the…

Read the full statement (141 words)

HardyCHROM™ CRE is a selective and differential chromogenic agar medium intended for the qualitative and presumptive detection from stool specimens of Escherichia coli that are non- susceptible to carbapenems as pink colonies and KES (Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae complex, and Serratia marcescens) that are non-susceptible to carbapenems as blue colonies.

HardyCHROM CRE is intended as an aid in the detection, identification of colonization and control of these bacteria in a healthcare setting. HardyCHROM™ CRE is not intended to diagnose infection or guide therapy. Results can be interpreted after incubation for 18-24 hours. Subculture to non-selective medium is required for confirming identification, antimicrobial susceptibility testing and epidemiological typing.

A lack of growth or the absence of pink or blue colonies on HardyCHROM™ CRE does not preclude the presence of Escherichia coli and KES that are non-susceptible to carbapenems.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K190553: HardyCHROM CRE.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K190553

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026